Journal of Neurochemistry · 1992 · 157 citations · 27 references
Life SciencesNeurosciencePharmacologyNeurochemistryNeurodegenerationNeuropharmacologyNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionNeurotransmissionParkinson DiseaseParkinsonian DisordersAmino AcidsDopaminergic NeurodegenerationDopaminergic NeuronsNigrostriatal Dopamine SystemNoncompetitive AntagonismNoncompetitive InhibitionParkinsonian DegenerationSystemic Administration
In cynomologus monkeys, systemic administration of MK-801, a noncompetitive antagonist for the N-methyl-D-aspartate receptor, prevented the development of the parkinsonian syndrome induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MK-801 also attenuated dopamine depletion in the caudate and putamen and protected dopaminergic neurons in the substantia nigra from the degeneration induced by the neurotoxin. Nevertheless, 7 days after MPTP administration in the caudate and putamen of monkeys also receiving MK-801, the levels of toxic 1-methyl-4-phenylpyridinium were even higher than those measured in monkeys receiving MPTP alone. This indicates that the protective action of MK-801 is not related to MPTP metabolism and strongly suggests that, in primates, the excitatory amino acids could play a crucial role in the mechanism of the selective neuronal death induced by MPTP.
27
Glutamate neurotoxicity and diseases of the nervous system
Dennis W. Choi · Neuron · 1988 · 8K citations
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
J. William Langston, Philip L. Ballard, James W. Tetrud et al. · Science · 1983 · 4.9K citations
Richard S. Burns, Chuang C. Chiueh, Sanford P. Markey et al. · Proceedings of the National Academy of Sciences · 1983 · 2.1K citations · Full text
Medicine, Neuroscience, Pharmacology +17
Jonathan A. Javitch, Robert J. D’Amato, Stephen M. Strittmatter et al. · Proceedings of the National Academy of Sciences · 1985 · 1.3K citations · Full text
Medicine, Neuroscience, Pharmacology +17